However, a great deal of clinical research has focused on the roles of ER in promoting breast cancer or osteoporosis, and several FDA-approved drugs exist to this day such as tamoxifen, toremifene, raloxifene, and fulvestrant that target SERMs or selective downregulation of ER in mammillary cells [143,144]. The gene discussed is ESR1; the disease is osteoporosis.